Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Trial of Adaptive Image Guided Standard or Dose Escalated Tumour Boost Radiotherapy in the Treatment of Transitional Cell Carcinoma of the Bladder

NCT02447549 is registered in ClinicalTrials.gov with Institute of Cancer Research, United Kingdom as lead sponsor.

NCT NCT02447549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02447549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Trial of Adaptive Image Guided Standard or Dose Escalated Tumour Boost Radiotherapy in the Treatment of Transitional Cell Carcinoma of the Bladder
Lead sponsor
Institute of Cancer Research, United Kingdom
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 21, 2015
Completion date
March 31, 2029
Enrollment
345 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer